Biotinylated polyurethane-urea nanoparticles for targeted theranostics in human hepatocellular carcinoma
Over the past years, significant efforts have been devoted to explore novel drug delivery and detection strategies for simultaneous therapy and diagnostics. The development of biotinylated polyurethane-urea nanoparticles as theranostic nanocarriers for targeted drug and plasmid delivery, for fluorescence detection of human hepatocellular carcinoma cells, is described herein. These targeted nanoparticles are specifically designed to incorporate biotin into the polymeric matrix, since many tumor types overexpress receptors for biotin as a mechanism to boost uncontrolled cell growth. The obtained nanoparticles were spherical, exhibited an average diameter ranging 110–145 nm, and showed no cytotoxicity in healthy endothelial cells. Biotinylated nanoparticles are selectively incorporated into the perinuclear and nuclear area of the human hepatocellular carcinoma cell line, HepG2, in division, but not into growing, healthy, human endothelial cells. Indeed, the simultaneous incorporation of the anticancer drugs, phenoxodiol or sunitinib, together with plasmid DNA encoding green fluorescent protein, into these nanoparticles allows a targeted pharmacological antitumor effect and furthermore, selective transfection of a reporter gene, to detect these cancer cells. The combined targeted therapy and detection strategy described here could be exploited for liver cancer therapy and diagnostics, with a moderate safety profile, and may also be a potential tool for other types of cancer.
Keywordscancer therapy DNA nanoparticles polyurethane theranostics
Unable to display preview. Download preview PDF.
12274_2014_678_MOESM1_ESM.pdf (751 kb)
- Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 2001, 53, 283–318.Google Scholar
- Soininen, S. K.; Lehtolainen-Dalkilic, P.; Karppinen, T.; Puustinen, T.; Dragneva, G.; Kaikkonen, M. U.; Jauhiainen, M.; Allart, B.; Selwood, D. L.; Wirth, T. et al. Targeted delivery via avidin fusion protein: Intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes. Eur. J. Pharm. Sci. 2012, 47, 848–856.CrossRefGoogle Scholar
- Newell, P.; Toffanin, S.; Villanueva, A.; Chiang, D. Y.; Minguez, B.; Cabellos, L.; Savic, R.; Hoshida, Y.; Lim, K. H.; Melgar-Lesmes, P. et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 2009, 59, 725–733.CrossRefGoogle Scholar
- Chen, C.; Heng, Y. C.; Yu, C. H.; Chan, S. W.; Cheung, M. K.; Yu, P. H. F. In vitro cytotoxicity, hemolysis assay, and biodegradation behaviour of biodegradable poly(3-hydroxybutyrate)-poly(ethylene glycol)-poly (3-hydroxybutyrate) nanoparticles as potential drug carriers. J. Biomed. Mater. Res. A 2008, 87, 290–298.CrossRefGoogle Scholar
- Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D. A.; Torchilin, V. P.; Jain, R. K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res. 1995, 17, 3752–3756.Google Scholar
- Glendenning, J. L.; Barbachano, Y.; Norman, A. R.; Dearnaley, D. P.; Horwich, A.; Huddart, R. A. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010, 116, 2322–2331.Google Scholar
- Lopergolo, A.; Nicolini, V.; Favini, E.; Dal Bo, L.; Tortoreto, M.; Cominetti, D.; Folini, M.; Perego, P.; Castiglioni, V.; Scanziani, E. et al. Synergistic cooperation between sunitinib and Cisplatin promotes apoptotic cell death in human medullary thyroid cancer. J. Clin. Endocrinol. Metab. 2014, 99, 498–509.CrossRefGoogle Scholar
- Aguero, M. F.; Facchinetti, M. M.; Sheleg, Z.; Senderowicz, A. M. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res. 2005, 65, 3364–3373.Google Scholar
- Yao, C.; Wu, S. J.; Li, D. M.; Wang, Z. Y.; Yang, Y. J.; Yang, S. C.; Gu, Z. P. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in Vitro. Molecular Oncology 2012, 6, 392–404.CrossRefGoogle Scholar
- Mendel, D. B., Laird, A. D.; Xin, X. H.; Louie, S. G.; Christensen, J. G.; Li, G. M.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B. et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res., 2003, 9, 327–337.Google Scholar
© Tsinghua University Press and Springer-Verlag Berlin Heidelberg 2014